Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Non-profit
  • Arts
  • Technology
  • Books
  • Entertainment
ncarol.com

Baebies Announces FDA Acknowledgement of Emergency Use Notification for FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test – RT-PCR within 17 Minutes
ncarol.com/10109576

Trending...
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • Community-Based Marriage Enrichment Support
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
DURHAM, N.C.--(BUSINESS WIRE)--Baebies, a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, today announced that the U.S. Food & Drug Administration (FDA) acknowledged the company's Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on the FINDER® 1.5 Instrument. The company's FINDER SARS‑CoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.

"Our FINDER SARS-CoV-2 test combines the accuracy of RT-PCR testing with a rapid turn-around time, which is made possible by our innovative digital microfluidics technology," says Richard West, Co‑Founder and Chief Executive Officer of Baebies. "We are launching the FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test to address the continued need for access to fast and accurate testing in health care facilities with high complexity laboratories. Our team has worked tirelessly for the last year to bring this to market and we are very excited to reach this important milestone."

The FINDER 1.5 platform includes a toaster-sized instrument and disposable single-use cartridge and features:
  • Small footprint at just 8 inches wide with a commercial tablet interface
  • Easy and intuitive workflow
  • Quick installation and no specialized training needed
  • Digital microfluidic technology, which minimizes sample and reagent volumes

Development of the FINDER SARS-CoV-2 Test was supported in part by funds from the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) initiative. The underlying digital microfluidics (DMF) technology is a method to programmably manipulate tiny droplets of liquid by electrical control of surface tension on a disposable cartridge. Baebies' DMF technology is protected by several hundred patents.

More on ncarol.com
  • O2 Fitness Opens New Signature Location in Pittsboro, NC
  • Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
  • Lamaze International and Plumtree Baby Launch New Childbirth Education Materials
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST

Digital microfluidics supports multifunctional assay methods – including molecular, immunoassay, and chemistry – on the same cartridge. Currently under FDA 510(k) review, FINDER tests for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic defect leading to anemia and severe jaundice. FINDER can efficiently test for G6PD deficiency from low blood volume (50 µL) with a turn-around time of approximately 15 minutes after sample introduction. Additionally, Baebies has a robust development pipeline and recently won the prestigious 2020 AACC Disruptive Technology Award for FINDER in a tight competition emerging as the next innovative testing solution that will transform patient care.

"In development of our FINDER SARS-CoV-2 Test, we focused on accelerating RT-PCR and sample processing for rapid results through several innovations – all made possible by digital microfluidics," noted Vamsee Pamula, co-founder and President. "This technology powers both our diagnostic platform, FINDER, and FDA-authorized newborn screening platform, SEEKER. Baebies' core focus still remains neonatal and pediatric diagnostics, however, the current COVID-19 pandemic doesn't distinguish between children and adults – everyone is at risk."

About Baebies

More on ncarol.com
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Walnut Hills Launches Off-Grid Hempcrete Homes and Eco-Retreat in Western NC
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives

Baebies - guided by the vision that "everyone deserves a healthy start" - develops and commercializes products and services that enable early disease detection and comprehensive diagnosis. Baebies has shipped over 10 million tests. Baebies' products include SEEKER®, an FDA-authorized and CE-marked high throughput newborn screening platform, and FINDER®, a CE-marked flexible, single sample testing platform that is currently not commercially available in the U.S. The FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test have been validated but FDA's independent review of this validation is pending. Our mission is to save lives and make lives better for all by bringing new technologies, new tests and new hope to children, parents and healthcare professionals worldwide. Baebies is headquartered in Durham, North Carolina. For more information, visit baebies.com and follow on LinkedIn, Twitter and YouTube.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Bang Bang Burgers and Orrman's Cheese Shop Unleash The Mac Daddy for National Mac & Cheese Day
  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
  • Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
  • Community-Based Marriage Enrichment Support
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Scott Burton Releases Chaos: The Weight of a Memory, a Poetic Journey Through What Still Lingers
  • The Business Hyve Opens Waitlist for Groundbreaking Community Built for Small Business Success
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
_catLbl0 _catLbl1

Popular on ncarol.com

  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 112
  • csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
  • Mauro Schnaidman named as Managing Director in Miami, Florida
  • Let's Talk Series: At the Crossroads: Immigration Today
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • Beyond the Template: Why Custom Web Design is a Power Move for Small Businesses
  • DumpEmDumpsterRentals.com Launches in Charlotte, Offering 10% Off 3-Day Rentals
  • Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague

Similar on ncarol.com

  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment
  • Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
  • AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute